Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cellectar Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CLRB
Nasdaq
2834
https://www.cellectar.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cellectar Biosciences Inc
Q4 2023 Cellectar Biosciences Inc Earnings Call
- Mar 28th, 2024 2:09 am
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
- Mar 27th, 2024 10:40 am
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
- Mar 20th, 2024 10:40 am
Cellectar Biosciences to Present at the 36th Annual Roth Conference
- Mar 14th, 2024 12:52 pm
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
- Mar 4th, 2024 11:40 am
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Feb 7th, 2024 11:40 am
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
- Jan 30th, 2024 11:40 am
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
- Jan 25th, 2024 11:40 am
Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient
- Jan 22nd, 2024 11:40 am
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical Data
- Jan 16th, 2024 11:40 am
Cellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline Results
- Jan 12th, 2024 11:44 am
Cellectar Biosciences Partners with MiBA, a Data Subsidiary of American Oncology Network, to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting
- Jan 11th, 2024 11:40 am
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia
- Jan 8th, 2024 11:30 am
Cellectar Biosciences to Announce Top-line Data from WM Pivotal Trial on January 8, 2024
- Jan 3rd, 2024 1:30 pm
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation
- Dec 19th, 2023 1:30 pm
Cellectar Biosciences Strengthens Intellectual Property Protection for its PDC Platform
- Dec 12th, 2023 1:30 pm
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
- Dec 5th, 2023 1:30 pm
Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation
- Nov 23rd, 2023 6:32 pm
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q3 2023 Earnings Call Transcript
- Nov 4th, 2023 4:36 pm
Cellectar to Release Top-line Data from WM Pivotal Trial During the JP Morgan Healthcare Conference the Week of January 8, 2024
- Nov 2nd, 2023 11:30 am
Scroll